What we do Ishita Drugs & Industries Ltd manufactures active pharmaceutical ingredients, drug intermediates, fine chemicals, and excipients, supplying major Indian pharma companies and exporting globally. |
Founded in 1,992 |
Market share A reputable player in Indian pharma ingredient manufacturing with exports worldwide and a strong GMP-compliant production base. |
Problem solved Providing quality, cost-effective pharmaceutical ingredients domestically to reduce import dependence, supporting the pharma industry’s growth. |
Top clients or who we serve Leading pharmaceutical companies in India; B2B focused, with expanding export markets globally. |
Key management - |
Our journey and innovations Established in 1992, built vertically integrated production from drug intermediates to formulations; developed improved norfloxacin technology; ongoing facility upgrades for compliance and capacity. |
Where we operate Manufacturing facilities in Gujarat, India; products supplied across India and exported internationally. |
Top products or what we offer Active pharma ingredients, drug intermediates, excipients, and finished dosage forms. |
Top brands - |
Raw materials needed Chemical intermediates and raw materials for API and excipient synthesis. |
Raw materials supplier - |
Recurring vs cyclical contribution Revenues from regular pharmaceutical ingredient sales; moderately recurring with some cyclical fluctuations. |
Our industry position Recognized domestic manufacturer with GMP-certified plants, seeking growth via compliance upgrades and export expansion. |
Financial highlights FY 2024-25 revenue approx. Rs 15.33 crore; net profit Rs 0.87 crore; highest-ever net profit recorded. |
Geographical revenue split Predominantly India with exports to multiple countries internationally. |
Order book - |
Whats driving growth Facility upgrades for regulatory compliance, cost reduction, new product introductions, and entry into regulated export markets. |
Our future plans Upgrading manufacturing facilities per Revised Schedule M; launching new products; expanding export presence; possible debt funding for capex. |
Our green promise - |
Our people and values Focus on compliance, ethical conduct, employee training, and anti-harassment policies; cultural emphasis on integrity and transparency. |
Key challenges ahead Facility compliance with Revised Schedule M; potential production disruptions during upgrades; competition and raw material price volatility. |
Interesting facts Company achieved highest ever net profit in FY 2024-25 despite slight revenue dip; continuous R&D led to improved norfloxacin production. |
Risks and strategy Mitigate regulatory risks via planned upgrades and expert consultancy; maintain internal controls and risk management policies. |
